[Media Releases] Interprotein and LegoChem Sign Collaboration Agreement to Develop VEGF Inhibitor to Treat Solid Tumors (Interprotein, 30 Sep 2010)
Title: Interprotein and LegoChem Sign Collaboration Agreement to Develop VEGF Inhibitor to Treat Solid Tumors Publication: Interprotein website Date: 30 Sep 2010 URL: link to website
Interprotein Corporation and LegoChem Biosciences, Inc. announced that they have signed a collaboration agreement on VEGF inhibitor programme for further optimization and the development of novel, orally active drugs to replace current anti-VEGF antibody therapies for the treatment of various solid tumors by suppressing tumor angiogenesis.
About LegoChem Biosciences LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC). |